Public company snapshot, recent ticker-linked headlines, and a path into evidence-backed AI research.
Latest price
$146.73
-0.14%
Alpha Vantage · 11/6/2026
Adjusted daily closes · 252 observations · as of Nov 6, 2026
1 month
+3.1%
3 months
+12.7%
6 months
+33.5%
1 year
+76.1%
Year to date
+42.3%
52-week range
$83.32 – $155.53
Latest reported period: Sep 30, 2026
Market cap
$361.73B
P/E
147.5
P/B
8.1
P/S
5.4
Revenue
$67.38B
Net income
$2.45B
Diluted EPS
0.98
Gross margin
71.80%
Net margin
3.60%
Return on equity
5.30%
Total debt
$53.78B
Cash
$9.55B
Free cash flow
$14.75B
Reported quarterly values, newest first
| Period | Revenue | Net income | Gross margin | Net margin | Free cash flow |
|---|---|---|---|---|---|
| Sep 30, 2026 | $18.09B | $5.07B | 72.90% | 28.00% | $5.52B |
| Jun 30, 2026 | $16.61B | -$1.34B | 73.50% | -8.00% | $4.48B |
| Mar 31, 2026 | $16.29B | -$4.24B | 74.20% | -26.00% | $2.93B |
| Dec 31, 2025 | $16.4B | $2.96B | 66.20% | 18.10% | $1.82B |
| Sep 30, 2025 | $17.28B | $5.79B | 77.70% | 33.50% | $6.84B |
| Jun 30, 2025 | $15.81B | $4.43B | 77.50% | 28.00% | $2.53B |
| Mar 31, 2025 | $15.53B | $5.08B | 78.00% | 32.70% | $1.17B |
| Dec 31, 2024 | $15.62B | $3.74B | 75.50% | 24.00% | $2.51B |
Reported figures can reflect company reporting conventions, restatements, or sector-specific accounting. Verify against filings before relying on a valuation comparison.
StoreSubscribeSign InMy SubscriptionsFounder's ClubSwingTraderLeaderboardMarketSurgeeIBDIBD DigitalIBD LiveCustomer CenterMy Stock ListsEmail PreferencesHelp & SupportSign OutSearch stocks or...
Original sourceThe exterior view of the entrance to Merck headquarters in Rahway, New Jersey, on Feb. 5, 2024.Spencer Platt | Getty ImagesMerck on Thursday topped third-quarter estimates and hiked its adjusted profit...
Original sourceSupport WBURModerna and Merck recently released remarkable new results of the personalized cancer vaccine.Here & Now's Scott Tong speaks with Matthew Herper, a senior writer at STAT, the health and...
Original sourceMerck presented its mRNA melanoma vaccine trial data at a European cancer conference this weekend. Results are promising: The vaccine reduces recurrence and death alongside an immunotherapy drug.
Original sourceMADRID — In a testament to clinicians’ interest in Merck and Moderna’s personalized cancer vaccine data at this year’s European Society for Medical Oncology conference, the ... ...
Original source